[Potential for infusion correction of COVID-19-associated endotheliopathy].
I S SimutisV A RatnikovA N ScheglovO V NikolaevaG A BoyarinovA A SapeginL B GaikovayaD A EvteevaK N ZamyatinaPublished in: Terapevticheskii arkhiv (2023)
Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.
Keyphrases
- coronavirus disease
- sars cov
- inflammatory response
- low dose
- lipopolysaccharide induced
- cardiovascular events
- early onset
- respiratory syndrome coronavirus
- cardiovascular disease
- risk factors
- sensitive detection
- stem cells
- lps induced
- mesenchymal stem cells
- living cells
- type diabetes
- risk assessment
- immune response
- coronary artery disease
- clinical evaluation
- quantum dots